JP Morgan analyst Robbie Marcus maintains Conmed (NYSE:CNMD) with a Overweight and lowers the price target from $115 to $75.
JP Morgan Maintains Overweight on Conmed, Lowers Price Target to $75
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.